公开(公告)号：US20250019705A1

公开(公告)日：2025-01-16

申请号：US18745018

申请日：2024-06-17

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  DANA-FARBER CANCER INSTITUTE, INC.

Inventor： Ju Hee RYU ,  Ick Chan KWON ,  Youngji KO ,  Thomas M. ROBERTS ,  Jean J. ZHAO ,  Liya DING

IPC: C12N15/113 ,  A61K45/06 ,  A61K47/64 ,  A61K47/65 ,  A61P35/00

Abstract: Provided is BRCA-specific siRNA for enhancing the sensitivity of cancer cells to PARP inhibitors. According to the present disclosure, the siRNA can induce cancer cell death together with the PARP inhibitors in patients with wild-type BRCA genes with a low therapeutic effect of the PARP inhibitors, and the fusion protein-siRNA complex for siRNA delivery is up-taken into cells via CD47, and thus more specifically delivered to cancer cells while up-taken with high efficiency, thereby maximizing a desired cell death effect.

公开(公告)号：US20240159744A1

公开(公告)日：2024-05-16

申请号：US18041587

申请日：2021-08-12

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Ju Hee RYU ,  Ick Chan KWON ,  Kwangmeyung KIM ,  Han Young KIM ,  Eun-sun KIM

IPC: G01N33/542 ,  A61K47/64 ,  G01N33/574 ,  G01N33/68

CPC classification number: G01N33/542 ,  A61K47/642 ,  G01N33/57419 ,  G01N33/6893 ,  G01N2333/485

Abstract: The present disclosure relates to a cancer cell-specific complex for targeting cancer. The complex for targeting cancer according to the present disclosure includes EGF, but is affected more by lysosomal activity rather than the EGFR signaling pathway, and thus can overcome the shortcomings of the existing EGF therapy-based diagnostic and therapeutic compositions and provide successfully personalized and improved effects of treating, preventing and alleviating cancer.
A diagnostic composition according to the present disclosure enables the prediction of the anticancer performance of a therapeutic composition of the present disclosure in a subject, and thus enables anticancer treatment to be designed stably.

公开(公告)号：US20210179681A1

公开(公告)日：2021-06-17

申请号：US17118767

申请日：2020-12-11

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung KIM ,  Ju Hee RYU ,  Hong Yeol YOON ,  Man Kyu SHIM ,  Suah YANG

IPC: C07K14/47 ,  C07K16/28 ,  A61K47/10 ,  A61P35/00

Abstract: The present disclosure relates to a pharmaceutical composition for combination therapy for preventing or treating cancer, which contains a first pharmaceutical ingredient containing a drug conjugate wherein an anticancer agent is bound at one end of an amphiphilic peptide represented by SEQ ID NO 1 and a poloxamer; and a second pharmaceutical ingredient containing an anti-PD-L1 antibody; as active ingredients. The pharmaceutical composition significantly inhibits cancer growth in in-vivo experiments and exhibits an effect of significantly enhancing immunotherapeutic effect by activating immune cells in cancerous tissues.
In particular, the pharmaceutical composition for combination therapy according to the present disclosure has superior tumor accumulation efficiency and selectivity as compared to existing anticancer agents, and is very stable with little toxicity to normal tissues other than cancerous tissues.

公开(公告)号：US20140288300A1

公开(公告)日：2014-09-25

申请号：US13936768

申请日：2013-07-08

Applicant: Korea Institute of Science and Technology

Inventor： Kwang Meyung KIM ,  Ick Chan KWON ,  Sang Yoon KIM ,  Ju Hee RYU ,  Eun Sung JUN ,  In San KIM

IPC: C07D499/78 ,  C07D409/14 ,  C07D498/08 ,  C07D209/62

CPC classification number: C07D499/78 ,  C07D209/62 ,  C07D409/14 ,  C07D498/08

Abstract: Disclosed is a drug-fluorophore complex for specific detection of tumor cells. Specifically, the drug-fluorophore complex includes a tumor cell-targeting drug penetrating tumor cells and non-tumor cells at different rates or levels, and a fluorescent substance chemically bonded to the tumor cell-targeting drug. The drug-fluorophore complex enables specific imaging of tumor cells only with high accuracy in a very simple manner without causing cytotoxicity.

Abstract translation: 公开了用于特异性检测肿瘤细胞的药物 - 荧光团复合物。 具体地，药物 - 荧光团复合物包括以不同速率或水平渗透肿瘤细胞和非肿瘤细胞的肿瘤细胞靶向药物和与肿瘤细胞靶向药物化学键合的荧光物质。 药物荧光团复合物能够以非常简单的方式以高精度进行肿瘤细胞的特异性成像，而不引起细胞毒性。

公开(公告)号：US20200087705A1

公开(公告)日：2020-03-19

申请号：US16568363

申请日：2019-09-12

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Ick Chan KWON ,  Ju Hee RYU ,  Young-Ji KO ,  Hye-sun KIM ,  Nam-hyuk CHO ,  Eun-Jeong YANG ,  Jae Won LEE

IPC: C12Q1/37 ,  G01N33/573

Abstract: A probe for measuring the activity of caspase-1 according to the present disclosure can specifically image cells or tissues where inflammatory response is induced because it is cleaved by reacting specifically with the active caspase-1 enzyme in vivo and in vitro and re-emits fluorescence. The probe for measuring the activity of caspase-1 can be used for various purposes, such as for imaging of cells or tissues where inflammatory response is induced, as a drug carrier, for screening of a drug inhibiting inflammatory response, etc.The probe for measuring the activity of caspase-1 is applicable both in vivo and in vitro, and can be used for various applications such as high-throughput screening for new drug development, early diagnosis of diseases, etc.

公开(公告)号：US20170216460A1

公开(公告)日：2017-08-03

申请号：US15169493

申请日：2016-05-31

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung KIM ,  Ju Hee RYU ,  Ick Chan KWON ,  Man Kyu SHIM ,  Hong Yeol YOON

IPC: A61K49/00 ,  G01N33/58 ,  G01N33/574 ,  C07K9/00

CPC classification number: A61K49/0056 ,  A61K47/555 ,  A61K49/0032 ,  A61K49/0052 ,  C07K5/1016 ,  C07K5/1019 ,  C07K9/001 ,  G01N33/57496 ,  G01N33/581 ,  G01N2333/96466

Abstract: The present disclosure relates to a glycopeptide targeting cancer cells and a contrast agent kit containing the same. The glycopeptide is one wherein an azide reporting monosaccharide is bound to a substrate peptide. As the substrate peptide is specifically cleaved by cathepsin B in cancer cells, an azide reporting monosaccharide is expressed onto the cell surface via metabolic glycoengineering, thereby providing a target for action as a contrast agent. Accordingly, because the azide is exposed to the cell surface only by cathepsin B, as it is specifically expressed in cancer cells, in particular in metastatic cancer cells, while it is limitedly expressed in normal cells and is hardly excreted out the cells, the cancer cells can be selectively imaged by an azide-specific contrast agent.

公开(公告)号：US20140147493A1

公开(公告)日：2014-05-29

申请号：US14071803

申请日：2013-11-05

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ick Chan KWON ,  Kwang Meyung KIM ,  Sun Hwa KIM ,  In-Cheol SUN ,  Jin Hee NA ,  Sangmin LEE ,  Ju Hee RYU

IPC: A61K48/00 ,  A61K9/127

CPC classification number: A61K9/127 ,  C12N15/88 ,  C12Q1/686 ,  C12Q2563/159 ,  C12Q2563/161

Abstract: Disclosed is an efficient carrier for gene delivery to cells based on PCR. The PCR-based gene delivery carrier includes: a shell composed of neutral liposomes; and template DNA and PCR components including polymerase, dNTPs and primers for amplification of the template DNA by PCR, within an inner space defined by the shell. The gene delivery carrier enhances the gene loading efficiency of neutral liposomes without cytotoxicity. Further disclosed is a method for preparing the gene delivery carrier.

Abstract translation: 公开了基于PCR的基因递送至细胞的有效载体。 基于PCR的基因递送载体包括：由中性脂质体组成的壳; 和模板DNA和PCR组分，包括聚合酶，dNTP和引物，用于通过PCR扩增模板DNA，在由壳定义的内部空间内。 基因递送载体增强了中性脂质体的基因负载效率，而没有细胞毒性。 进一步公开的是制备基因递送载体的方法。